Optical fluorescent technology has the potential to deliver real time imaging of cancer into the operating room and the clinic. To determine the efficacy of fluorescently labeled antivascular endothelial growth factor (VEGF) antibody to be used as a cancer specific optical contrast agent to guide surgical resections, we evaluated the sensitivity and specificity of this agent to detect microscopic residual disease in a preclinical model of head and neck squamous cell carcinoma (HNSCC). Using a flank murine model, mice were xenografted with SCC-1 tumor cells and injected with anti-VEGF antibody (bevacizumab) conjugated to an optically active fluorophore (Cy5.5). Tumors underwent sub-total resections and were assessed for the presence of residual disease by fluorescent stereomicroscopy. Expected positive and negative biopsies were taken according to the presence or absence of fluorescence, respectively. Histology was used to confirm the presence or absence of disease.
Introduction
Determination of adequate surgical margins in oncologic resections at present relies on gross inspection and palpation by the surgeon as well as histologic information provided by frozen section. Unfortunately, these subjective methods result in positive or close surgical margins in almost 40% of cases (1, 2) . Because positive margins predict poor survival (2), accurate identification of intraoperative margins may be of significant value in guiding the surgeon during oncologic resections. Identification of a cancer specific optical contrast agent could provide surgeons with real-time, objective information about the tumor margins, and the presence of residual disease thereby improving outcomes and decreasing morbidity by minimizing unnecessary tissue resection. Fluorescent optical imaging has been utilized in neurosurgery to guide surgical resections and in both abdominal and thoracic surgery to identify sentinel lymph nodes (8, 9) . Fluorescent imaging has revolutionized molecular biology and is increasingly being evaluated for a variety of applications in tumor detection (3-7).
Fluorescent compounds (fluorophores) absorb light at one wavelength and emit at another wavelength. The technique of using a fluorescent microscope that can image the emission wavelength from a fluorophore has been successfully introduced to image non-specific lymphatic contrast agents in the operating room for sentinel lymph node mapping (8, 9) . Although fluorophores have insufficient tissue penetration for whole body imaging, in the surgical setting where tissue planes are exposed, optical fluorescence has significant potential. The clinical utility of a fluorescent contrast agent will depend on the sensitivity, specificity and toxicity of the cancer specific probe.
We have previously published our data on the utilization of FIND (Fluorescent Imaging in Neoplasm Detection) with respect to control of surgical margins. Our prior studies investigated anti-epidermal growth factor receptor (EGFR) antibody as a potential cancer specific contrast agent for determining the status of margins in surgery for head and neck squamous cell cancer (HNSCC) and found a high level of sensitivity and specificity in a human xenograft murine model (10). EGFR is highly overexpressed and is upregulated early in tumor progression (11, 12) . Such upregulation is seen in various receptors and growth factors in malignant cells and provides the basis for many tumor specific diagnostic and therapeutic modalities (11) (12) (13) (14) (15) (16) (17) . This study utilized bevacizumab (also known as Avastin, Genentech, CA) which is a recombinant humanized monoclonal IgG1 antibody against human vascular endothelial growth factor. Bevacizumab selectively binds to VEGF, a potent promoter of tumor angiogenesis (13, 18) . It is currently indicated only in the treatment of metastatic carcinoma of the colon and rectum. VEGF, however, is known to be highly expressed by HNSCC and recent studies indicate that VEGF likely plays an important role in progression of HNSCC (15-17, 19, 20, 21) . We hypothesize that fluorescently labeled bevacizumab is sensitive and specific in the detection of microscopic disease in vivo.
Materials and Methods

Reagents
We used bevacizumab (Avastin, Genentech, San Fransisco, CA), a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human VEGF. Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF (1). Bevacizumab has a molecular weight of approximately 149 kilodaltons. Cy5.5 (CyDye deoxynucleotides, GE Healthcare; Piscataway, NJ) was used as the far-red fluorescent marker. Cy5.5 has a broad absorption peak with its maximum at 683nm. Its emission maximum when coupled to IgG is at 707nm, with a relative quantum yield of 0.28. Cy5.5 has a degree of labeling of 4.2 moles of dye per mole of protein using a ε of 250000 M -1 cm -1 at the absorbance maximum. Bevacizumab was incubated with Cy5.5 Reactive Dye (CyDye deoxynucleotides, Amersham Biosciences; Piscataway, NJ) in 0.15M phosphate buffer, pH 7.8 for 1.5 hours. The non-conjugated Cy5.5 was removed by Centricon Centrifugal Filter Unit, YM-30 (Millipore; Billerica, MA). All procedures were conducted under aseptic technique.
Animal Models
SCID male mice, age 4-6 weeks (Charles River Laboratories, Wilmington, MA), were obtained and housed in accordance with the institution's IACUC guidelines. All experiments were conducted and the animals euthanized according to our institution's IACUC guidelines. SCC-1 cells were obtained (Thomas Carey, University of Michigan, Ann Arbor, MI) and maintained in DMEM containing 10% FBS and supplemented with L-glutamine, penicillin, and streptomycin and incubated at 37 ºC in 5% CO 2 . SCC-1 cells (2 × 10 6 ) were injected into the flank of SCID mice. The conjugated antibody was systemically administered to each mouse via tail vein injection prior to imaging and resection. Previous studies performed in our lab determined 48 hours post-injection to be the optimal time for fluorescent imaging of this antibody-conjugate; resections were performed on euthanized mice at this time point. Stereomicroscopic imaging was performed before and after near-total tumor resection as well as each biopsy.
Prior to the initiation of the experiment, serial dosages (40-240 μg) of bevacizumab-Cy5.5 were evaluated until peak luminosity relative to background was identified at 165 μg. Using the flank model, tumors were incubated for approximately two weeks (tumor size 5 mm to 10 mm) and then each mouse was injected with 165ug of bevacizumab-Cy5.5 two days prior to imaging. Subtotal resection was performed approximately 48 hours after injection and microcup biopsy forceps (Hartmann Herzfeld cup shaped alligator forceps, 2 mm cup size, Medtronic, Jacksonville, FL) were used to sample the wound bed during fluorescent imaging. Biopsies were taken from areas of increased fluorescence in the tumor bed until a non-fluorescent background was obtained. The determination of what constituted significant fluorescence was subjective. Images taken after the administration of bevicizumab-Cy5.5 were compared to those taken initially in order to determine what constituted an increase in luminosity beyond the background. Once no further increased fluorescence was observed in the tumor bed, an equal number of negative biopsies were taken from the previously fluorescent areas of the tumor bed. Serial (bread loaf) histological sections and routine H&E staining were then performed on each biopsy specimen to assess the presence of any residual tumor.
Imaging
Human tumor xenografts were imaged using a custom-built Leica fluorescent stereomicroscope (Leica MZFL3 Stereo research microscope, Leica Microsystems, Bannockburn, IL) fitted with a Cy5.5 filter and an ORCA ER charge coupled device (CCD) camera (Hamamatsu, Bridgewater, NJ) to allow for real-time imaging of Cy5.5 fluorescence. Cy5.5 filter (Chroma filter set 41023) provided excitation between 630 and 670 nm and emission measured at 685 to 735 nm.
Gross images, brightfield and fluorescent images were obtained for each resection and biopsy. Fluorescence captured by the stereomicroscope was quantified after digital capture using ImageJ (http://rsb.info.nih.gov/ij/). For the images, the mean fluorescence intensity of the tumor was determined by outlining the tissue as a region of interest in ImageJ and capturing the mean luminosity. The mean luminosity (fluorescence intensity) of the selected area was measured in arbitrary units using a histogram constructed in Adobe Photoshop. As the background luminosity was negligible and present in all fluorescent images, it was not subtracted from the mean luminosity of the area of interest.
Statistical Analysis
The sensitivity, specificity, positive predictive value, and negative predictive value for detection of tumor cells by fluorescence were tested against the histological analysis of tumor samples. The formulas used were: (I) sensitivity = 100% × a/(a + c); (II) specificity = 100% × d/(b + d); (III) positive predictive value = 100% × a/(a + b); and (IV) negative predictive value = 100% × d/(c + d) using the standard 2 × 2 table for comparing a test of interest to a true diagnosis. Confidence limits were calculated for each comparison using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA) using the "exact" confidence intervals as described by Clopper and Pearson.
Results and Discussion
Currently surgeons rely on subtle tissue changes and frozen section for intraoperative assessment of tumor margins. This experiment was designed to further demonstrate the potential utility of fluorescently labeled anti-tumor antibodies to guide surgical resections or direct frozen section sampling intraoperatively.
Following systemic injection of bevacizumab-Cy5.5, mice bearing human head and neck squamous cell carcinoma xenografts were imaged over time using a Cy5.5 fluorescent filter. The peak luminosity was noted to occur between 24 and 48 hours (Figure 1 ). Subtotal resections of flank tumors were performed approximately 48 hours after systemic injection of bevicizumab-Cy5.5. Brightfield and real-time fluorescent stereomicroscopy was used to image the tumor initially and following partial resection (Figure2). Real-time fluorescent stereomicroscopy was then used to guide further biopsies within the tumor bed ( Figure 3 ). To validate fluorescent findings, biopsies from the wound bed included both fluorescent areas and non-fluorescent areas (Figure 4) . Fluorescence predicted the presence of tumor in 17 of 18 biopsies; a sensitivity of 80.9% (Table I) . When all fluorescent tissue had been re-moved via biopsy, areas of non-fluorescence were biopsied. Fluorescence failed to predict the presence of disease in 4 of 15 biopsies; a specificity of 91.7% (Table I) .
The concept of using fluorescently targeted agents has been largely neglected by the imaging community because fluorescent probes have very limited tissue penetration. However, in the surgical setting, where the underlying tissues are exposed, the real-time capabilities of optical imaging may be useful to the clinician. Other rapidly developing imaging technologies such as positron emission tomography (PET) cannot provide clinicians with real-time information (22) . Prior to our previous experiments, this technique had not yet been evaluated as a tool to assess surgical margins. The sensitivity and specificity of bevicizumab-Cy5.5 is slightly lower than that found using cetuximab-Cy5.5 in the same model. Additionally, fluorescent imaging of non-tumor regions revealed very low baseline luminosity in mice injected with bevacizumab-Cy5.5; this was not seen in animals that received cetuximab-Cy5.5. This is likely due to the fact that cetuximab targets EGFR, a membrane bound receptor, while bevacizumab targets VEGF, a growth factor found free in the blood. As such, some degree of diffuse fluorescence is expected with a proportionate increase in intensity as blood flow increases, as is the case in neoplasms. While normal murine tissue distant from the xenograft showed no significant increase in fluorescence above the baseline, it is unclear how situations associated with increased blood flow (e.g., wound healing) would affect luminosity. Because bevicizumab-Cy5.5 does not bind with murine VEGF (23), background luminosity may represent circulating human VEGF produced by the xenograft.
Although optical imaging technology can be readily adapted to the operating room, it has not been widely used because currently approved fluorophores lack tumor specificity. Two recent advances in biotechnology have led to generation of tumor specific fluorescent probes. In response to demands from molecular biologists, novel fluorophores have been generated that can be linked to antibodies without disrupting the ligand binding site (24-26). Additionally, the development of many therapeutic antibodies designed to selectively bind to tumor cells allows for tumor specific delivery of the fluorophore (12, 13, (27) (28) (29) (30) ).
In the current study, we further demonstrate the potential utility of FIND. Previously, cetuximab was evaluated us- ing two preclinical models with different tumor growth patterns and different methods of analysis to assess the utility of FIND; both resulted in similar findings. The specificity in both models was consistently 100%. In our present study we found the sensitivity using bevacizumab to be 80.9%, suggesting that fluorescence within the wound bed can be confidently considered to be equivalent to the presence of malignant cells but that some normal tissue will also be removed due to fluorescence. The specificity was found to be 91.7%, indicating again that negative fluorescence could be shown to be free of tumor most of the time. As such, our results suggest that minimal background fluorescence is present within the tumor bed during near-infrared optical imaging, and small nests of tumor cells may not always be detected. Additionally, the determination of what constitutes significant fluorescence is subjective; much like in the setting of an oncologic resection.
As VEGF is a blood-borne molecule, it is likely that some parts of the tumor are not exposed to the conjugate (i.e., reduced blood flow or partial necrosis) and, therefore, do not exhibit fluorescence. Our studies suggest that an antibody that targets a tumor-bound molecule or receptor may be a better choice than one that is directed against a non-bound molecule. It is possible that the use of multiple antibodies di-rected at different tumor-specific molecules or receptors used simultaneously could improve the sensitivity.
With this study, we provide further evidence that fluorescently labeled anti-tumor antibodies exhibit high sensitivity and specificity with respect to determining the status of surgical margins in a murine xenograft model. The sensitivity and specificity of bevacizumab as compared with previously tested cetuximab was slightly lower. This data supports the need for further investigation of fluorescently labeled antibodies, such as bevacizumab and cetuximab, as cancerspecific contrast agent to guide surgical therapy or detect disease in the clinical setting. 
